Opti Capital Management’s Novavax NVAX Stock Holding History

Opti Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,000	Closed	-$39K	–	24
2018 Q4	$39K	Buy	+1,000	New	+$38.8K	0.02%	25

Other funds holding NVAX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Opti Capital Management's NVAX Position: Q1 2019 in Review

Opti Capital Management sold out of Novavax (NVAX) in Q1 2019, closing a stake of 1,000 shares — an estimated $39K sold.

Opti Capital Management first reported a position in NVAX in Q4 2018 and held it in 1 quarter. The position peaked at $39K in Q4 2018. 142 funds tracked by Wall St. Rank hold NVAX as of Q1 2019.

Opti Capital Management reported no remaining Novavax position as of Q1 2019 after selling out during the quarter.
Opti Capital Management sold 1,000 Novavax shares in Q1 2019, an estimated $39K.
Opti Capital Management first reported a position in Novavax in Q4 2018 and held it in 1 quarter.
Opti Capital Management's Novavax position peaked at $39K in Q4 2018.
142 funds tracked by Wall St. Rank held Novavax as of Q1 2019.

Based on Opti Capital Management's 13F filing for Q1 2019, filed 13 May 2019.